These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38567789)

  • 1. Efficacy and safety of oral factor Xa inhibitors versus vitamin-K antagonists in the early phase after acute ischemic stroke or TIA in the real-world setting: The PRODAST study.
    Diener HC; Grosse GM; Hüsing A; Stang A; Kuklik N; Brinkmann M; Maurer GD; Soda H; Pohlmann C; Hilker-Roggendorf R; Popovic N; Kraft P; Mackert BM; Eschenfelder CC; Weimar C
    Eur Stroke J; 2024 Sep; 9(3):696-703. PubMed ID: 38567789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study.
    Grosse GM; Hüsing A; Stang A; Kuklik N; Brinkmann M; Nabavi D; Sparenberg P; Weissenborn K; Gröschel K; Royl G; Poli S; Michalski D; Eschenfelder CC; Weimar C; Diener HC;
    Int J Stroke; 2023 Dec; 18(10):1169-1177. PubMed ID: 37306492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
    Bruins Slot KM; Berge E
    Cochrane Database Syst Rev; 2013 Aug; (8):CD008980. PubMed ID: 23925867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale, Design and Methods of the Prospective Record of the Use of Dabigatran in Patients with Acute Stroke or TIA (PRODAST) Study.
    Grosse GM; Weimar C; Kuklik N; Hüsing A; Stang A; Brinkmann M; Eschenfelder CC; Diener HC;
    Eur Stroke J; 2021 Dec; 6(4):438-444. PubMed ID: 35342819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
    Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
    Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
    Blin P; Dureau-Pournin C; Bénichou J; Cottin Y; Mismetti P; Abouelfath A; Lassalle R; Droz C; Moore N
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):81-103. PubMed ID: 31254174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of stroke in patients with prior VKA or DOAC: A population-based real-world registry analysis.
    Mayer-Suess L; Rinner H; Lang W; Greisenegger S; Mikšová D; Gattringer T; Enzigner C; Sykora M; Vosko M; Mutzenbach JS; Ferrari J; Kiechl S; Knoflach M;
    Eur Stroke J; 2024 Jun; 9(2):418-423. PubMed ID: 38161290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
    Paciaroni M; Agnelli G; Falocci N; Tsivgoulis G; Vadikolias K; Liantinioti C; Chondrogianni M; Bovi P; Carletti M; Cappellari M; Zedde M; Ntaios G; Karagkiozi E; Athanasakis G; Makaritsis K; Silvestrelli G; Lanari A; Ciccone A; Putaala J; Tomppo L; Tatlisumak T; Abdul-Rahim AH; Lees KR; Alberti A; Venti M; Acciarresi M; D'Amore C; Becattini C; Mosconi MG; Cimini LA; Soloperto R; Masotti L; Vannucchi V; Lorenzini G; Tassi R; Guideri F; Acampa M; Martini G; Sohn SI; Marcheselli S; Mumoli N; De Lodovici ML; Bono G; Furie KL; Tadi P; Yaghi S; Toni D; Letteri F; Tassinari T; Kargiotis O; Lotti EM; Flomin Y; Mancuso M; Maccarrone M; Giannini N; Bandini F; Pezzini A; Poli L; Padovani A; Scoditti U; Denti L; Consoli D; Galati F; Sacco S; Carolei A; Tiseo C; Gourbali V; Orlandi G; Giuntini M; Chiti A; Giorli E; Gialdini G; Corea F; Ageno W; Bellesini M; Colombo G; Monaco S; Maimone Baronello M; Karapanayiotides T; Caso V
    J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29220330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry.
    Yoshimoto T; Toyoda K; Ihara M; Inoue H; Yamashita T; Suzuki S; Akao M; Atarashi H; Ikeda T; Okumura K; Koretsune Y; Shimizu W; Tsutsui H; Hirayama A; Yasaka M; Maruyama H; Teramukai S; Kimura T; Morishima Y; Takita A; Yamaguchi T
    Stroke; 2022 Aug; 53(8):2549-2558. PubMed ID: 35440169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
    Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
    Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
    J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.